

**From:** [DeBoer, Briana](#)  
**To:** [mary.hart@bms.com](mailto:mary.hart@bms.com)  
**Cc:** [Roberts, Mark](#); [Ullrich, Elizabeth](#)  
**Subject:** your letter dated May 31, 2018  
**Date:** Wednesday, June 06, 2018 10:50:00 AM

---

License No. 06-27843-02  
Docket No. 030-29266  
Control No. 608976

To: Mary C. Hart, RSO, Associate Director, EHS  
From: Briana DeBoer, NRC

As discussed on June 6, 2018 via telephone call with Mary Hart, Bristol-Myers Squibb RSO, Ryan Fahey, DDES Project Manager, Mark Roberts, NRC, and Briana DeBoer, NRC, below are the questions we have regarding your request.

1. The Decommissioning Plan proposes initiation of decommissioning work the week of June 4<sup>th</sup>, 2018, and PCO-Chemistry is scheduled to stop use of radioactive material on July 13, 2018. Please confirm that, as we discussed, decontamination activities in the PCO-Chemistry suite will not commence until active work with radionuclides has been completed.
2. Based on a records review it appears radionuclides from previous license amendments (Chlorine-36 and Nickle-63) are not listed on Table 3.1. Based on our review, please confirm that you have not previously possessed Chlorine-36 and that any Nickle-63 sources, now generally licensed, will be dispositioned in accordance with any applicable requirements in 10 CFR 31.
3. Please describe the methodology for disposition of the Cesium-137 source listed on your license?

Thank you,

*Briana DeBoer*

Health Physicist  
Decommissioning, ISFSI, and Reactor Health Physics Branch  
USNRC Region 1 DNMS  
(610) 337-5370